个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Lu, S.[1] * ; Zhang, Y.[2] ; Zhang, G.[3] ; Zhou, J.[4] ; Cang, S.[5] ; Cheng, Y.[6] ; Wu, G.[7] ; Cao, P.[8] ; Lv, D.[9] ; Jian, H.[10] ; Chen, C.[11] ; Jin, X.[12] ; Tian, P.[13] ; Wang, K.[14] ; Jiang, G.[15] ; Chen, G.[16] ; Chen, Q.[17] ; Zhao, H.[18] ; Ding, C.[19] ; Ding, L.[20] ;
机构： [1]Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Med Oncol Dept, Shanghai, Peoples R China [2]Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Thorac Oncol, Hangzhou, Peoples R China [3]Zhengzhou Univ, Affiliated Hosp 1, Dept Resp Med, Zhengzhou, Peoples R China [4]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Resp Dis,Thorac Dis Ctr, Hangzhou, Peoples R China [5]Henan Prov Peoples Hosp, Oncol, Zhengzhou, Henan, Peoples R China [6]Jilin Canc Hosp, Med Oncol, Changchun, Jilin, Peoples R China [7]Huazhong Univ Sci & Technol, Ctr Canc, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China [8]Cent South Univ, Xiangya Hosp 3, Oncol, Changsha, Peoples R China [9]Taizhou Hosp Zhejiang Prov, Dept Resp Med, Taizhou, Peoples R China [10]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China [11]Wenzhou Med Univ, Nanbaixiang Site, Affiliated Hosp 1, Dept Resp Med, Wenzhou, Peoples R China [12]Ningxia Med Univ, Gen Hosp, Med Oncol Dept, Yinchuan, Ningxia, Peoples R China [13]Sichuan Univ, West China Hosp, West China Sch Med, Dept Resp & Crit Care Med, Chengdu, Peoples R China [14]Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp Med, East Gate 1, Hangzhou, Peoples R China [15]Dongguan Peoples Hosp, Dept Med Oncol, Dongguan, Peoples R China [16]Harbin Med Univ, Canc Hosp, Dept Resp Med, Harbin, Peoples R China [17]Fuzhou Pulom Hosp Fujian, Oncol, Fuzhou, Peoples R China [18]Anhui Med Univ, Affiliated Hosp 2, Dept Resp & Crit Care Med, Hefei, Peoples R China [19]Hebei Med Univ North Gate, Hosp 4, Dept Resp Med, Shijiazhuang, Hebei, Peoples R China [20]Betta Pharmaceut Co Ltd, Hangzhou, Peoples R China
出处：
DOI： 10.1016/j.annonc.2023.10.565
ISSN：
基金：
Betta Pharmaceuticals Co., Ltd.
语种：
外文
WOS：
中科院分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Med Oncol Dept, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Lu S.,Zhang Y.,Zhang G.,et al.Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)[J].ANNALS OF ONCOLOGY.2023,34:S1654-S1654.doi:10.1016/j.annonc.2023.10.565.
APA：
Lu, S.,Zhang, Y.,Zhang, G.,Zhou, J.,Cang, S....&Ding, L..(2023).Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).ANNALS OF ONCOLOGY,34,
MLA：
Lu, S.,et al."Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)".ANNALS OF ONCOLOGY 34.(2023):S1654-S1654

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号